Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
NOVATO, Calif., Jan. 04, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 10:30 am PT in San Francisco.
The live and archived webcast of the company presentation will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
